{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T20:05:51Z","timestamp":1794254751487,"version":"4.9.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"name":"Translational Research Grant from Leukemia & Lymphoma Society"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s12885-016-2331-0","type":"journal-article","created":{"date-parts":[[2016,5,3]],"date-time":"2016-05-03T17:02:28Z","timestamp":1462294948000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Expression of the cereblon binding protein argonaute 2 plays an important role for multiple myeloma cell growth and survival"],"prefix":"10.1186","volume":"16","author":[{"given":"Qinqin","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue-xian","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Langlais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Erickson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Xin","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moulun","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanxiao","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence J.","family":"Mandarino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiu-bao","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,5,3]]},"reference":[{"key":"2331_CR1","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1002\/ajh.21913","volume":"86","author":"SV Rajkumar","year":"2011","unstructured":"Rajkumar SV. Multiple myeloma: 2011 update on diagnosis, risk-stratification, and management. Am J Hematol. 2011;86:57\u201365.","journal-title":"Am J Hematol"},{"key":"2331_CR2","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1093\/abbs\/gmt142","volume":"46","author":"X Chang","year":"2014","unstructured":"Chang X, Zhu Y, Shi C, Stewart AK. Mechanism of immunomodulatory drugs\u2019 action in the treatment of multiple myeloma. Acta Biochim Biophys Sin. 2014;46:240\u201353.","journal-title":"Acta Biochim Biophys Sin"},{"key":"2331_CR3","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1126\/science.1177319","volume":"327","author":"T Ito","year":"2010","unstructured":"Ito T, Ando H, Suzuki T, Ogura T, Hotta K, Imamura Y, Yamaguchi Y, Handa H. Identification of a primary target of thalidomide teratogenicity. Science. 2010;327:1345\u201350.","journal-title":"Science."},{"key":"2331_CR4","doi-asserted-by":"crossref","first-page":"4771","DOI":"10.1182\/blood-2011-05-356063","volume":"118","author":"YX Zhu","year":"2011","unstructured":"Zhu YX, Braggio E, Shi CX, Bruins LA, Schmidt JE, Van Wier S, Chang XB, Bjorklund CC, Fonseca R, Bergsagel PL, et al. Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood. 2011;118:4771\u20139.","journal-title":"Blood"},{"key":"2331_CR5","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/nature05175","volume":"443","author":"S Angers","year":"2006","unstructured":"Angers S, Li T, Yi X, MacCoss MJ, Moon RT, Zheng N. Molecular architecture and assembly of the DDB1-CUL4A ubiquitin ligase machinery. Nature. 2006;443:590\u20133.","journal-title":"Nature"},{"key":"2331_CR6","first-page":"287","volume":"2","author":"XB Chang","year":"2011","unstructured":"Chang XB, Stewart AK. What is the functional role of the thalidomide binding protein cereblon? Int J Biochem Mol Biol. 2011;2:287\u201394.","journal-title":"Int J Biochem Mol Biol"},{"key":"2331_CR7","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.sbi.2010.08.010","volume":"20","author":"ES Zimmerman","year":"2010","unstructured":"Zimmerman ES, Schulman BA, Zheng N. Structural assembly of cullin-RING ubiquitin ligase complexes. Curr Opin Struct Biol. 2010;20:714\u201321.","journal-title":"Curr Opin Struct Biol"},{"key":"2331_CR8","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1111\/j.1471-4159.2005.03344.x","volume":"94","author":"S Jo","year":"2005","unstructured":"Jo S, Lee KH, Song S, Jung YK, Park CS. Identification and functional characterization of cereblon as a binding protein for large-conductance calcium-activated potassium channel in rat brain. J Neurochem. 2005;94:1212\u201324.","journal-title":"J Neurochem"},{"key":"2331_CR9","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3109\/01677060903567849","volume":"24","author":"JJ Higgins","year":"2010","unstructured":"Higgins JJ, Tal AL, Sun X, Hauck SC, Hao J, Kosofosky BE, Rajadhyaksha AM. Temporal and spatial mouse brain expression of cereblon, an ionic channel regulator involved in human intelligence. J Neurogenet. 2010;24:18\u201326.","journal-title":"J Neurogenet."},{"key":"2331_CR10","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.febslet.2009.01.018","volume":"583","author":"B Hohberger","year":"2009","unstructured":"Hohberger B, Enz R. Cereblon is expressed in the retina and binds to voltage-gated chloride channels. FEBS Lett. 2009;583:633\u20137.","journal-title":"FEBS Lett"},{"key":"2331_CR11","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.bbamcr.2011.01.005","volume":"1813","author":"KM Lee","year":"2011","unstructured":"Lee KM, Jo S, Kim H, Lee J, Park CS. Functional modulation of AMP-activated protein kinase by cereblon. Biochim Biophys Acta.\u00a02011;1813:448\u201355.","journal-title":"Biochim Biophys Acta."},{"key":"2331_CR12","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.bbrc.2012.09.108","volume":"427","author":"KM Lee","year":"2012","unstructured":"Lee KM, Lee J, Park CS. Cereblon inhibits proteasome activity by binding to the 20S core proteasome subunit beta type 4. Biochem Biophys Res Commun. 2012;427:618\u201322.","journal-title":"Biochem Biophys Res Commun"},{"key":"2331_CR13","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1126\/science.1244917","volume":"343","author":"G Lu","year":"2014","unstructured":"Lu G, Middleton RE, Sun H, Naniong M, Ott CJ, Mitsiades CS, Wong KK, Bradner JE, Kaelin Jr WG. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of ikaros proteins. Science. 2014;343:305\u20139.","journal-title":"Science"},{"key":"2331_CR14","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1126\/science.1244851","volume":"343","author":"J Kronke","year":"2014","unstructured":"Kronke J, Udeshi ND, Narla A, Grauman P, Hurst SN, McConkey M, Svinkina T, Heckl D, Comer E, Li X, et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science. 2014;343:301\u20135.","journal-title":"Science"},{"key":"2331_CR15","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1182\/blood-2014-02-557819","volume":"124","author":"YX Zhu","year":"2014","unstructured":"Zhu YX, Braggio E, Shi CX, Kortuem KM, Bruins LA, Schmidt JE, Chang XB, Langlais P, Luo M, Jedlowski P, et al. Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma. Blood. 2014;124:536\u201345.","journal-title":"Blood"},{"key":"2331_CR16","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nature13527","volume":"512","author":"ES Fischer","year":"2014","unstructured":"Fischer ES, Bohm K, Lydeard JR, Yang H, Stadler MB, Cavadini S, Nagel J, Serluca F, Acker V, Lingaraju GM, et al. Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide. Nature. 2014;512:49\u201353.","journal-title":"Nature"},{"key":"2331_CR17","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.cell.2007.10.032","volume":"131","author":"S Diederichs","year":"2007","unstructured":"Diederichs S, Haber DA. Dual role for argonautes in microRNA processing and posttranscriptional regulation of microRNA expression. Cell. 2007;131:1097\u2013108.","journal-title":"Cell"},{"key":"2331_CR18","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1126\/science.1102513","volume":"305","author":"J Liu","year":"2004","unstructured":"Liu J, Carmell MA, Rivas FV, Marsden CG, Thomson JM, Song JJ, Hammond SM, Joshua-Tor L, Hannon GJ. Argonaute2 is the catalytic engine of mammalian RNAi. Science. 2004;305:1437\u201341.","journal-title":"Science"},{"key":"2331_CR19","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1101\/gad.1565607","volume":"21","author":"D O\u2019Carroll","year":"2007","unstructured":"O\u2019Carroll D, Mecklenbrauker I, Das PP, Santana A, Koenig U, Enright AJ, Miska EA, Tarakhovsky A. A slicer-independent role for argonaute 2 in hematopoiesis and the microRNA pathway. Genes Dev. 2007;21:1999\u20132004.","journal-title":"Genes Dev"},{"key":"2331_CR20","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/bjh.12708","volume":"164","author":"AK Gandhi","year":"2014","unstructured":"Gandhi AK, Kang J, Havens CG, Conklin T, Ning Y, Wu L, Ito T, Ando H, Waldman MF, Thakurta A, et al. Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors ikaros and aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.). Br J Haematol. 2014;164:811\u201321.","journal-title":"Br J Haematol"},{"key":"2331_CR21","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.leukres.2013.08.015","volume":"38","author":"SR Schuster","year":"2014","unstructured":"Schuster SR, Kortuem KM, Zhu YX, Braggio E, Shi CX, Bruins LA, Schmidt JE, Ahmann G, Kumar S, Rajkumar SV, et al. The clinical significance of cereblon expression in multiple myeloma. Leuk Res. 2014;38:23\u20138.","journal-title":"Leuk Res"},{"key":"2331_CR22","doi-asserted-by":"crossref","first-page":"20280","DOI":"10.1074\/jbc.M001109200","volume":"275","author":"Y Hou","year":"2000","unstructured":"Hou Y, Cui L, Riordan JR, Chang XB. Allosteric interactions between the two non-equivalent nucleotide binding domains of multidrug resistance protein MRP1. J Biol Chem. 2000;275:20280\u20137.","journal-title":"J Biol Chem"},{"key":"2331_CR23","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.2741\/2865","volume":"13","author":"MP Perron","year":"2008","unstructured":"Perron MP, Provost P. Protein interactions and complexes in human microRNA biogenesis and function. Front Biosci. 2008;13:2537\u201347.","journal-title":"Front Biosci"},{"key":"2331_CR24","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0092-8674(04)00045-5","volume":"116","author":"DP Bartel","year":"2004","unstructured":"Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281\u201397.","journal-title":"Cell"},{"key":"2331_CR25","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1160\/TH11-12-0836","volume":"107","author":"T Treiber","year":"2012","unstructured":"Treiber T, Treiber N, Meister G. Regulation of microRNA biogenesis and function. Thromb Haemost. 2012;107:605\u201310.","journal-title":"Thromb Haemost"},{"key":"2331_CR26","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1080\/10428190802535114","volume":"50","author":"M Fabbri","year":"2009","unstructured":"Fabbri M, Croce CM, Calin GA. MicroRNAs in the ontogeny of leukemias and lymphomas. Leuk Lymphoma. 2009;50:160\u201370.","journal-title":"Leuk Lymphoma"},{"key":"2331_CR27","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.2353\/ajpath.2009.080794","volume":"174","author":"R Visone","year":"2009","unstructured":"Visone R, Croce CM. MiRNAs and cancer. Am J Pathol. 2009;174:1131\u20138.","journal-title":"Am J Pathol"},{"key":"2331_CR28","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1182\/blood-2014-02-553842","volume":"124","author":"AY So","year":"2014","unstructured":"So AY, Sookram R, Chaudhuri AA, Minisandram A, Cheng D, Xie C, Lim EL, Flores YG, Jiang S, Kim JT, et al. Dual mechanisms by which miR-125b represses IRF4 to induce myeloid and B-cell leukemias. Blood. 2014;124:1502\u201312.","journal-title":"Blood"},{"key":"2331_CR29","doi-asserted-by":"crossref","first-page":"7904","DOI":"10.1073\/pnas.0908441107","volume":"107","author":"Y Zhou","year":"2010","unstructured":"Zhou Y, Chen L, Barlogie B, Stephens O, Wu X, Williams DR, Cartron MA, van Rhee F, Nair B, Waheed S, et al. High-risk myeloma is associated with global elevation of miRNAs and overexpression of EIF2C2\/AGO2. Proc Natl Acad Sci U S A. 2010;107:7904\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2331_CR30","doi-asserted-by":"crossref","first-page":"9284","DOI":"10.1073\/pnas.0800803105","volume":"105","author":"S Diederichs","year":"2008","unstructured":"Diederichs S, Jung S, Rothenberg SM, Smolen GA, Mlody BG, Haber DA. Coexpression of argonaute-2 enhances RNA interference toward perfect match binding sites. Proc Natl Acad Sci U S A. 2008;105:9284\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2331_CR31","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1038\/sj.leu.2402295","volume":"15","author":"D Gupta","year":"2001","unstructured":"Gupta D, Treon SP, Shima Y, Hideshima T, Podar K, Tai YT, Lin B, Lentzsch S, Davies FE, Chauhan D, et al. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia. 2001;15:1950\u201361.","journal-title":"Leukemia"},{"key":"2331_CR32","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/sj.leu.2402745","volume":"17","author":"S Lentzsch","year":"2003","unstructured":"Lentzsch S, LeBlanc R, Podar K, Davies F, Lin B, Hideshima T, Catley L, Stirling DI, Anderson KC. Immunomodulatory analogs of thalidomide inhibit growth of Hs sultan cells and angiogenesis in vivo. Leukemia. 2003;17:41\u20134.","journal-title":"Leukemia"},{"key":"2331_CR33","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1365-2141.2007.06841.x","volume":"140","author":"N Reddy","year":"2008","unstructured":"Reddy N, Hernandez-Ilizaliturri FJ, Deeb G, Roth M, Vaughn M, Knight J, Wallace P, Czuczman MS. Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo. Br J Haematol. 2008;140:36\u201345.","journal-title":"Br J Haematol"},{"key":"2331_CR34","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1038\/sj.bjc.6600607","volume":"87","author":"K Dredge","year":"2002","unstructured":"Dredge K, Marriott JB, Macdonald CD, Man HW, Chen R, Muller GW, Stirling D, Dalgleish AG. Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects. Br J Cancer. 2002;87:1166\u201372.","journal-title":"Br J Cancer"},{"key":"2331_CR35","doi-asserted-by":"crossref","first-page":"5509","DOI":"10.1016\/j.bmcl.2005.08.086","volume":"15","author":"T Noguchi","year":"2005","unstructured":"Noguchi T, Fujimoto H, Sano H, Miyajima A, Miyachi H, Hashimoto Y. Angiogenesis inhibitors derived from thalidomide. Bioorg Med Chem Lett. 2005;15:5509\u201313.","journal-title":"Bioorg Med Chem Lett"},{"key":"2331_CR36","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/j.0022-202X.2005.23830.x","volume":"125","author":"E Heere-Ress","year":"2005","unstructured":"Heere-Ress E, Boehm J, Thallinger C, Hoeller C, Wacheck V, Birner P, Wolff K, Pehamberger H, Jansen B. Thalidomide enhances the anti-tumor activity of standard chemotherapy in a human melanoma xenotransplatation model. J Invest Dermatol. 2005;125:201\u20136.","journal-title":"J Invest Dermatol"},{"key":"2331_CR37","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.mvr.2005.01.002","volume":"69","author":"K Dredge","year":"2005","unstructured":"Dredge K, Horsfall R, Robinson SP, Zhang LH, Lu L, Tang Y, Shirley MA, Muller G, Schafer P, Stirling D, et al. Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and akt phosphorylation in vitro. Microvasc Res. 2005;69:56\u201363.","journal-title":"Microvasc Res"},{"key":"2331_CR38","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/1756-8722-7-40","volume":"7","author":"S Wu","year":"2014","unstructured":"Wu S, Yu W, Qu X, Wang R, Xu J, Zhang Q, Li J, Chen L. Argonaute 2 promotes myeloma angiogenesis via microRNA dysregulation. J Hematol Oncol. 2014;7:40.","journal-title":"J. Hematol. Oncol."},{"key":"2331_CR39","doi-asserted-by":"crossref","first-page":"108","DOI":"10.4331\/wjbc.v2.i6.108","volume":"2","author":"P Kastner","year":"2011","unstructured":"Kastner P, Chan S. Role of Ikaros in T-cell acute lymphoblastic leukemia. World J Biol Chem. 2011;2:108\u201314.","journal-title":"World J Biol Chem"},{"key":"2331_CR40","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1023\/A:1015372322419","volume":"7","author":"C Schmitt","year":"2002","unstructured":"Schmitt C, Tonnelle C, Dalloul A, Chabannon C, Debre P, Rebollo A. Aiolos and ikaros: regulators of lymphocyte development, homeostasis and lymphoproliferation. Apoptosis. 2002;7:277\u201384.","journal-title":"Apoptosis"},{"key":"2331_CR41","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1182\/blood-2009-09-243980","volume":"115","author":"RE Tiedemann","year":"2010","unstructured":"Tiedemann RE, Zhu YX, Schmidt J, Yin H, Shi CX, Que Q, Basu G, Azorsa D, Perkins LM, Braggio E, et al. Kinome-wide RNAi studies in human multiple myeloma identify vulnerable kinase targets, including a lymphoid-restricted kinase, GRK6. Blood. 2010;115:1594\u2013604.","journal-title":"Blood"},{"key":"2331_CR42","doi-asserted-by":"crossref","first-page":"30962","DOI":"10.1074\/jbc.272.49.30962","volume":"272","author":"XB Chang","year":"1997","unstructured":"Chang XB, Hou YX, Riordan JR. ATPase activity of purified multidrug resistance-associated protein [published erratum appears in J Biol Chem 1998 Mar 27;273(13):7782]. J Biol Chem. 1997;272:30962\u20138.","journal-title":"J Biol Chem"},{"key":"2331_CR43","doi-asserted-by":"crossref","first-page":"39245","DOI":"10.1074\/jbc.M112.394148","volume":"287","author":"P Langlais","year":"2012","unstructured":"Langlais P, Dillon JL, Mengos A, Baluch DP, Ardebili R, Miranda DN, Xie X, Heckmann BL, Liu J, Mandarino LJ. Identification of a role for CLASP2 in insulin action. J Biol Chem. 2012;287:39245\u201353.","journal-title":"J Biol Chem"},{"key":"2331_CR44","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/0092-8674(87)90497-1","volume":"50","author":"RD Palmiter","year":"1987","unstructured":"Palmiter RD, Behringer RR, Quaife CJ, Maxwell F, Maxwell IH, Brinster RL. Cell lineage ablation in transgenic mice by cell-specific expression of a toxin gene [published erratum appears in Cell 1990 Aug 10;62(3):following 608]. Cell. 1987;50:435\u201343.","journal-title":"Cell"},{"key":"2331_CR45","doi-asserted-by":"crossref","first-page":"11304","DOI":"10.1016\/S0021-9258(18)82125-1","volume":"268","author":"XB Chang","year":"1993","unstructured":"Chang XB, Tabcharani JA, Hou YX, Jensen TJ, Kartner N, Alon N, Hanrahan JW, Riordan JR. Protein kinase A (PKA) still activates CFTR chloride channel after mutagenesis of all 10 PKA consensus phosphorylation sites. J Biol Chem. 1993;268:11304\u201311.","journal-title":"J Biol Chem"},{"key":"2331_CR46","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/bjc.1989.9","volume":"59","author":"SP Cole","year":"1989","unstructured":"Cole SP, Downes HF, Slovak ML. Effect of calcium antagonists on the chemosensitivity of two multidrug-resistant human tumour cell lines which do not overexpress P-glycoprotein. Br J Cancer. 1989;59:42\u20136.","journal-title":"Br J Cancer"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-016-2331-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,16]],"date-time":"2024-06-16T05:28:14Z","timestamp":1718515694000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-016-2331-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,3]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["2331"],"URL":"https:\/\/doi.org\/10.1186\/s12885-016-2331-0","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,3]]},"article-number":"297"}}